Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Budulac, Simona E ^a   Vonk, Judith M ^a   Postma, Dirkje S ^a   Siedlinski, Mateusz ^a   Timens, Wim ^a   Boezen, Marike H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC RECEPTOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE; GENE CLUSTER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NACHR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SMOKING HABIT; WILD TYPE; GENETIC PREDISPOSITION; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; MULTIGENE FAMILY; NETHERLANDS; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RISK FACTOR; SMOKING; TOBACCO DEPENDENCE;

ADULT; COHORT STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIGENE FAMILY; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, NICOTINIC; RISK FACTORS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84858172069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033386     Document Type: Article

References (35)

1. Grabus SD, Martin BR, Brown SE, Damaj MI, (2006) Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) 184: 456-463.
2. Le Foll B, Goldberg SR, (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 184: 367-381.
3. Heath AC, Cates R, Martin NG, Meyer J, Hewitt JK, et al. (1993) Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. J Subst Abuse 5: 221-246.
4. Ingebrigtsen T, Thomsen SF, Vestbo J, van der Sluis S, Kyvik KO, et al. (2010) Genetic influences on chronic obstructive pulmonary disease- A twin study. Respir Med.
5. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT, (2003) The genetic determinants of smoking. Chest 123: 1730-1739.
6. Boezen HM, (2009) Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc 6: 701-703.
7. Willemse BW, Postma DS, Timens W, ten Hacken NH, (2004) The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 23: 464-476.
8. Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ, (2009) Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J 33: 468-480.
9. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. (2009) A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5: e1000421.
10. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
11. Chen X, Chen J, Williamson VS, An SS, Hettema JM, et al. (2009) Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 150B: 926-933.
12. Lambrechts D, Buysschaert I, Zanen P, Coolen J, Lays N, et al. (2010) The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 181: 486-493.
13. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, et al. (2008) A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 4: e1000125.
14. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, et al. (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16: 36-49.
15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO, (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119-1127.
16. Keskitalo K, Broms U, Heliovaara M, Ripatti S, Surakka I, et al. (2009) Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet 18: 4007-4012.
17. Piper ME, McCarthy DE, Baker TB, (2006) Assessing tobacco dependence: a guide to measure evaluation and selection. Nicotine Tob Res 8: 339-351.
18. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF, (1994) Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. Addict Behav 19: 33-39.
19. Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, et al. (2008) Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 32: 1158-1164.
20. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, et al. (2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161: 381-390.
21. Pianezza ML, Sellers EM, Tyndale RF, (1998) Nicotine metabolism defect reduces smoking. Nature 393: 750.
22. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24: 1212-1217.
23. Bondarev ML, Bondareva TS, Young R, Glennon RA, (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474: 85-93.
24. Fryer JD, Lukas RJ, (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288: 88-92.
25. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, et al. (2008) Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 147B: 712-719.
26. Mroziewicz M, Tyndale RF, (2010) Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 5: 17-29.
27. Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, et al. (2011) Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine Tob Res 13: 498-503.
28. Cunningham JA, Leatherdale ST, Selby PL, Tyndale RF, Zawertailo L, et al. (2011) Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. BMC Public Health 11: 741.
29. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, et al. (2005) A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 172: 329-333.
30. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Nolte IM, et al. (2006) Decorin and TGF-beta1 polymorphisms and development of COPD in a general population. Respir Res 7: 89.
31. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, et al. (2009) Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One 4: e4653.
32. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
33. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
34. Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, et al. (2008) Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 63: 1040-1045.
35. Celli BR, MacNee W, (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946.